Age Does Not Adversely Influence Outcomes Among Patients Older Than 60 Years Who Undergo Allogeneic Hematopoietic Stem Cell Transplant for AML and Myelodysplastic Syndrome
Bone Marrow Transplantation - United Kingdom
doi 10.1038/bmt.2017.182
Full Text
Open PDFAbstract
Available in full text
Date
September 4, 2017
Authors
Publisher
Springer Science and Business Media LLC